

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Hui CHEN et al.

Title: METHOD AND COMPOSITIONS FOR INHIBITING CELL PROLIFERATIVE DISORDERS

Prior Appl. No.: 09/953,933

Prior Appl. Filing Date: 09/18/2001

Examiner: Unassigned

Art Unit: Unassigned

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/953,933, filed 09/18/2001. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

## **TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

## **RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Date

**FOLEY & LARDNER**  
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5475  
Facsimile: (202) 672-5399

~~Respectfully submitted,~~

B

Beth A. Burrous  
Attorney for Applicant  
Registration No. 35,087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted:

(use as many sheets as necessary)

**Complete if Known**

Prior Application Number	09/953,933
Prior Appl. Filing Date	09/18/2001
First Named Inventor	Hui Chen
Group Art Unit	Unassigned
Examiner Name	Unassigned

Attorney Docket Number 038602-1585

Sheet 1 of 8

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	A1	08/179570		HIRTH et al.	
	A2	3,313,771		DRESSLER et al.	04-11-1967
	A3	5,217,999	A	LEVITZKI et al.	06-08-1993
	A4	5,302,606	A	SPADA et al.	04-12-1994
	A5	5,439,895	A	LEE et al.	08-08-1995
	A6	5,656,643	A	SPADA et al.	08-12-1997
	A7	5,700,823	A	HIRTH et al.	12-23-1997
	A8	5,712,395	A	APP et al.	07-27-1998

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Office <sup>3</sup>	Number <sup>4</sup>		
					T <sup>6</sup>
	A9	AU	31010/93	A Barker	07-22-1993
	A10	CA	2,069,857	A1 CIBA-GEIGY AG	12-01-1992
	A11	CA	2,086,968	A1 ZENECA LIMITED	06-23-1998
	A12	EP	0 520 722	A1 ZENECA LIMITED	12-27-1996
	A13	EP	0 537 742	B1 MITSUBISHI CHEMICAL CORPORATION	08-21-1996
	A14	EP	0 566 226	B1 ZENECA LIMITED	11-08-1995
	A15	GB	1,191,306	KOPPERS COMPANY	05-13-1970
	A16	GB	2,240,104	A FARMATALIA CARLO ERBA S.r.l.	07-24-1991

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: (use as many sheets as necessary)					<b>Complete if Known</b>	
Sheet	2	of	8		Prior Application Number	09/953,933
					Prior Appl. Filing Date	09/18/2001
					First Named Inventor	Hui Chen
					Group Art Unit	Unassigned
					Examiner Name	Unassigned
					Attorney Docket Number	038602-1585

<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	A17	WO	92/02444	A1	THE DOW CHEMICAL COMPANY	02-20-1992	
	A18	WO	92/20642	A1	RHONEPOULENC RORER INTERNATIONAL, INC.	11-26-1992	
	A19	WO	92/21641	A1	PFIZER INC.	12-10-1992	
	A20	WO	94/24095	A1	ABBOTT LABORATORIES	10-27-1997	
	A21	WO	94/26260	A1	YISSUM RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM	11-24-1994	
	A22	WO	95/24190	A2	SUGEN, INC. et al.	09-14-1995	

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>								
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						T <sup>6</sup>
	A23	AARONSON, S., "Growth Factors and Cancer," <u>Science</u> 254:1146-1153 (1991)						
	A24	<u>AFFLECK et al., Proc. Annu. Meeting American Associate Cancer Research</u> 34:A2298 (1993)						
	A25	ANAFI et al., "Selective Interactions of Transforming and Normal abl Proteins with ATP, Tyrosine-Copolymer Substrates, and Tyrphostins," <u>J. Bio. Chem.</u> 267:4518-4523 (1992)						
	A26	ANDREWS et al. (American Veterinary Medicine Association Panel on Euthanasia), "1993 Report of the AVMA Panel on Euthanasia," <u>J. American Veterinary Medicine Association</u> 202(2):229-249 (1993)						
	A27	BASELGA et al., "Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies," <u>J. of Natl. Cancer Institute</u> 85(16):1327-1333 (1993)						
	A28	BILDER et al., "Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells," <u>Am. J. Physiol.</u> 260 (Cell Physiol.29):C721-C730 (1991)						

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Prior Application Number</b>	09/953,933
Date Submitted: <i>(use as many sheets as necessary)</i>				<b>Prior Appl. Filing Date</b>	09/18/2001
				<b>First Named Inventor</b>	Hui Chen
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
Sheet	3	of	8	<b>Attorney Docket Number</b>	038602-1585

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>6</sup>
	A29	BIRCHALL et al., "Compositions for killing internal parasites containing 3-teri-alkyl-4-hydroxy-5-halobenzylidene-malononitriles," <u>Chemical Abstracts</u> 88:535 (1978)			
	A30	BRYCKAERT et al., "Inhibition of Platelet-Derived Growth Factor-Induced Mitogenesis and Tyrosine Kinase Activity in Cultured Bone Marrow Fibroblasts by Tyrphostins," <u>Exp. Cell Research</u> 199:255-261 (1992)			
	A31	CARAGLIA et al., "Cytosine Arabinoside Increases the Binding of 125I-Labelled Epidermal Growth Factor and 125I-Transferrin and Enhances the In Vitro Targeting of Human Tumour Cells With Anti- (Growth Factor Receptor) mAb," <u>Cancer Immunol Immunother</u> 37:150-156, (1993)			
	A32	CARBONI et al., "Cyanocarbon Chemistry. XI. Malononitrile Dimer," <u>J. Am. Chem. Soc.</u> 80:2838-2840 (1958)			
	A33	CARRAWAY and CANTLEY, "A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling," <u>Cell</u> 78:5-8 (1994)			
	A34	CARRAWAY et al., "The erbB3 Gene Product Is a Receptor for Heregulin," <u>J. Biol. Chem.</u> 269:14303-14306 (1994)			
	A35	DATI et al., "Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells," <u>Oncogene</u> 5:1001-1006 (1990)			
	A36	DECKER and LOHMANN-MATTHES, "A Quick and Simple Method for the Quantitation of Lactate Dehydrogenase Release in Measurements of Cellular Cytotoxicity and Tumor Necrosis Factor (TNF) Activity," <u>J. Immunol. Methods</u> 115:61 (1988)			
	A37	DOUGALL et al., "The Neu-Oncogene: Signal Transduction Pathways, Transformation Mechanisms and Evolving Therapies," <u>Oncogene</u> 9:2109, (1994)			
	A38	FERRIS et al., "Synthesis of Zuinazoline Nucleosides from Ribose and Anthranilonitrile. Application of Phase-Transfer Catalysis in Nucleoside Synthesis," <u>J. Org. Chem.</u> 44(2):173-178 (1979)			
	A39	FLOEGE et al., "Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo," <u>Kidney International</u> 43S:47-54 (1993)			
	A40	GAZIT et al., "Tyrphostins. 1. Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors," <u>J. Med. Chem.</u> 32:2344-2352 (1989)			
	A41	GAZIT et al., "Tyrphostins. 2. Heterocyclic and $\alpha$ -Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," <u>J. Med. Chem.</u> 34:1896-1907 (1991)			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<i>Complete if Known</i>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Prior Application Number</b>	09/953,933
Date Submitted: <i>(use as many sheets as necessary)</i>				<b>Prior Appl. Filing Date</b>	09/18/2001
				<b>First Named Inventor</b>	Hui Chen
				<b>Group Art Unit</b>	Unassigned
				<b>Examiner Name</b>	Unassigned
Sheet	4	of	8	<b>Attorney Docket Number</b>	038602-1585

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A42	GAZIT et al., "Tyrphostins. 3. Structure-Activity Relationship Studies of a $\alpha$ -Substituted Benzylidenemalononitrile 5-S-Aryltyrphostins" <u>J. Med. Chem.</u> 36:3556-3564 (1993)	
	A43	GOTTARDIS et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumorstatic Action of Tamoxifen," <u>J. Steroid Biochem.</u> 30(1-6):331-314 (1988)	
	A44	GRANTHAM; F.H., "Role of Hormones in the Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted Into Athymic Nude Mice," <u>J. Natl. Cancer Inst.</u> 67:51-56, (1981)	
	A45	HALE et al., "Prognostic value of epidermal growth factor receptor expression in cervical carcinoma," <u>J. Clin. Pathol.</u> 46:149-153 (1993)	
	A46	HARRIS et al., "Breast Cancer (First of Three Parts)," <u>New England J. of Medicine</u> 327(5):319-328 (1992)	
	A47	HOEKSTRA et al., "Differential effects of steurosporine and tyrophostins on receptor tyrosine kinase autophosphorylation and peptide substrate phosphorylation," <u>Experimental Therapeutics</u> from 84 <sup>th</sup> Annual Meeting of American Association for Cancer Research, Vol. 34, #2455 (1993)	
	A48	HONEGGER et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 5:199-209 (1987)	
	A49	HUDZIAK et al., "p185 <sup>HER2</sup> Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor," <u>Molecular and Cellular Biology</u> 9:1165-1172 (1989)	
	A50	ISSIDORIDES and HADDADIN, "Benzofurazan Oxide. II. Reactions with Enolate Anions," <u>J. Org. Chem.</u> 31:4067-4068 (1966)	
	A51	KARAMERIS et al., "Expression of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFR) in Gastric and Colorectal Carcinomas," <u>Path. Res. Pract.</u> 189:133-137, (1993)	
	A52	KAUR et al., "Tyrophostin induced growth inhibition: correlation with effect on p210 <sup>bcr-abl</sup> autokinase activity in K562 chronic myelogenous leukemia," <u>Anti-Cancer Drugs</u> , 1994, pp. 213-222, Vol. 5, © Rapid Communications of Oxford Ltd.	
	A53	KOENDERS et al., "Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study," <u>Breast Cancer Resrch and Treatment</u> 25:21-27 (1993)	
	A54	KORZENIEWSKI and CALLEWAERT, "An Enzyme-Release Assay for Natural Cytotoxicity," <u>J. Immunol. Methods</u> 64:313 (1983)	

Examiner Signature:	Date Considered:
---------------------	------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Prior Application Number	09/953,933
Date Submitted: <i>(use as many sheets as necessary)</i>				Prior Appl. Filing Date	09/18/2001
				First Named Inventor	Hui Chen
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	5	of	8	Attorney Docket Number	038602-1585

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A55	LEE and SALEMNICK, "Purine N-Oxides, LXII. 2,4-Dioxopyrido[2,3-d]pyrimidine N-Oxides," <u>J. Org. Chem.</u> 40(24):3608-3610 (1975)		
	A56	LEVITZKI, A.; "Tyrphostins – Potential Antiproliferative Agents and Novel Molecular Tools," <u>Biochem. Pharm.</u> 40(5):913-918 (1990)		
	A57	LEY and SENG, "Synthesen unter Verwendung von Benzofuroxan," <u>Synthesis</u> 1975:415-422 (1975)		
	A58	LOTTA, T. et al., <u>Journal of Computer-Aided Molecular Design</u> 6:253-272 (1992).		
	A59	LYALL et al., "Tyrphostins Inhibit Epidermal Growth Factor (EGF)-Receptor Tyrosine Kinase Activity in Living Cells and EGF-stimulated Cell Proliferation," <u>J. Bio. Chem.</u> 264:14503-14509 (1989)		
	A60	MARSHALL, E., "Search for a Killer: Focus Shifts from Fat to Hormones," <u>Science</u> 259:618-621 (1993)		
	A61	MITUS and ROSENTHAL, "Ch. 30 – Adult Leukemias," <u>Textbook of Clinical Oncology</u> , Holleb, Fink and Murphy eds., pp. 410-432.		
	A62	MOSMANN, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assay," <u>J. Immunol. Methods</u> 65:55-63 (1983)		
	A63	OHMICHI et al., "The Tyrosine Kinase Inhibitor Tyrphostin Blocks the Cellular Actions of Nerve Growth Factor," <u>Biochemistry</u> 32:4650-4658 (1993)		
	A64	O'ROURKE and KALTER, "Ch. 28-Leukemia," <u>Clinical Oncology</u> , Weiss et al. eds. Norwalk Conn.		
	A65	OSBORNE et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," <u>Cancer Research</u> 45:584-590 (1985)		
	A66	OSHEROV et al., "Selective Inhibition of the EGF and Neu receptors by Tyrophostins," <u>J. Cell Biochem.</u> S17A:237 (1993)		
	A67	OSHEROV et al., "Selective Inhibition of the Epidermal Growth Factor and HER2/Neu Receptors by Tyrophostins," <u>J. Bio. Chem.</u> 268:11134-11142 (1993)		
	A68	OZZELLO, I. and SORDAT, M., "Behavior of Tumors Produced by Transplantation of Human Mammary Cell Lines in Athymic Nude Mice," <u>Eur. J. Cancer</u> 16:553-559 (1980)		
	A69	PAWSON and SCHLESSINGER, "SH2 and SH3 domains," <u>Current Biology</u> 3(7):434-441 (1993)		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	6	of	8	Prior Application Number	09/953,933
				Prior Appl. Filing Date	09/18/2001
				First Named Inventor	Hui Chen
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	038602-1585

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	A70	PETERSON and BARNES, "Genistein and Biochanin A Inhibit the Growth of Human Prostate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation," <u>The Prostate</u> 22:335-345 (1993)			T <sup>6</sup>
	A71	PIGOTT et al., "Expression of epidermal growth factor receptor in human glioblastoma multiforme," <u>Brit. J. of Neurosurgery</u> 7:261-265 (1993)			
	A72	PLOWMAN et al., "Heregulin induces tyrosine phosphorylation of HER4/p180 <sup>erbB4</sup> ," <u>Nature</u> 366:473-475 (1993)			
	A73	PUI and RIVERA, "Ch. 31 – Childhood Leukemias," <u>Textbook of Clinical Oncology</u> , Holleb, Fink and Murphy eds., pp. 433-452			
	A74	REDDY et al., "Inhibition of Breast Cancer Cell Growth in Vitro by a Tyrosine Kinase Inhibitor," <u>Cancer Research</u> 52:3636-3641 (1992)			
	A75	RENDU et al., "Inhibition of Platelet Activation by Tyrosine Kinase Inhibitors," <u>Biochem. Pharm.</u> 44(5):881-888 (1992)			
	A76	RUBENS, "Improving Treatment for Advanced Breast Cancer," <u>Cancer Surveys</u> 18:199-209 (1993)			
	A77	RUSCH et al., "Differential Expression of the Epidermal Growth Factor Receptor and Its Ligands in Primary Non-Small Cell Lung Cancers and Adjacent Benign Lung," <u>Cancer Research</u> 53:2379-2385 (1993)			
	A78	RYGAARD, J. and POVLSEN, C.O., "Heterotransplantation of a Human Malignant Tumour to "Nude" Mice," <u>Acta Pathol. Microbiol. Scand.</u> 77:758-760 (1969)			
	A79	SAMANTA, "Ligand and p185 <sup>c-neu</sup> density govern receptor interactions and tyrosine kinase activation," <u>Proc. Natl. Acad. Sci. USA</u> 91:1711-1715 (1994)			
	A80	SAMMES, et al., " $\alpha$ -Cyano-Sulphonyl Chlorides: Their Preparation and reactions with Amines, Alcohols, and Enamines," <u>J. Chem. Soc. (C)</u> , 2151 (1971)			
	A81	SARUP, "Characterization of an Anti-p185 <sup>HER2</sup> Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth," <u>Growth Regulation</u> 1:72-82 (1991)			
	A82	SCHLESSINGER, "Signal Transduction by Allosteric Receptor Oligomerization," <u>J. Trends Biochem. Sci.</u> 13:443-447, (1988)			
	A83	SCHLESSINGER, J. and ULLRICH, A., "Growth Factor Signaling by Receptor Tyrosine Kinases," <u>Neuron</u> 9(3):383-391, (1992)			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted:

(use as many sheets as necessary)

**Complete if Known**

Prior Application Number	09/953,933
Prior Appl. Filing Date	09/18/2001
First Named Inventor	Hui Chen
Group Art Unit	Unassigned
Examiner Name	Unassigned

Attorney Docket Number 038602-1585

Sheet

7

of

8

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A84	SCHORNAGEL et al., "Synthesis and Evaluation of 2,4-Diaminoquinazoline Antifolates with Activity Against Methotrexate-Resistant Human Tumor Cells," <u>Biochem. Pharm.</u> 33(20):3251-3255 (1984)	
	A85	SCOTT et al., "p185 <sup>HER2</sup> Signal Transduction in Breast Cancer Cells," <u>J. Bio. Chem.</u> 266(22):14300-14305 (1991)	
	A86	SEIBERT et al., "Clonal Variation of MCF-7 Breast Cancer Cells in Vitro and in Athymic Nude Mice," <u>Cancer Research</u> 43:2223-2239 (1983)	
	A87	SHAFIE and GRANTHAM, "Role of Hormones in Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted into Athymic Nude Mice," <u>J. Natl. Cancer Institute</u> 67(1):51-56 (1981)	
	A88	SHEPARD, "Monoclonal Antibody Therapy of Human Cancer: taking the HER2 Protooncogene to the Clinic," <u>Journal of Clinical Immunology</u> 11:117-126 (1991)	
	A89	SKEHAN et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," <u>J. Natl. Cancer Inst.</u> 82:1107-1112 (1990)	
	A90	SLAMON et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene," <u>Science</u> 235:177-185 (1987)	
	A91	SLIWOWSKI et al., "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin," <u>J. Biol. Chem.</u> 269:14661-14665 (1994)	
	A92	STEIN et al., "The SH2 domain protein GRB-7 is co-amplified, overexpressed and in a tight complex with HER2 in breast cancer," <u>EMBO Journal</u> 13(6):1331-1340 (1994)	
	A93	ULLRICH and SCHLESSINGER, "Signal Transduction by Receptors with Tyrosine Kinase Activity," <u>Cell</u> 61:203, (1990)	
	A94	WADA et al., "Anti-receptor Antibodies Reverse the Phenotype of Cells Transformed by Two Interacting Proto-Oncogene Encoded Receptor Proteins," <u>Oncogene</u> 5:489-495, (1990)	
	A95	WADA et al., "Intermolecular Association of the p185neu Protein and EGF Receptor Modulates EGF Receptor Function," <u>Cell</u> 61:1339, (1990)	
	A96	WARRI, A.M., et al., "Estrogen Suppression of erbB2 Expression is Associated with Increased Growth Rate of ZR-75-1 Human Breast Cancer Cells In Vitro and in Nude Mice," <u>Int. J. Cancer</u> , 49:616-623, (1991)	

Examiner Signature

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Prior Application Number	09/953,933
Date Submitted: <i>(use as many sheets as necessary)</i>				Prior Appl. Filing Date	09/18/2001
				First Name Inventor	Hui Chen
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	038602-1585
Sheet	8	of	8		

#### **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

**Examiner-Signature:** \_\_\_\_\_ **Date Considered:** \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C.